

Physician Login

Healthcare Professionals

Patients & Caregivers

About Oncotype IQ

 Contact Us

ON-DEMAND WEBINAR: Optimizing Molecular Testing in NSCLC

Optimizing Molecular Profiling in Non-Small Cell Lung Cancer

Available On-Demand

Speakers

Dr. Mark Kris MD
Memorial Sloan Kettering Cancer Center

Dr. Edgardo Santos, MD, FACP
Florida Precision Oncology

Dr. David Gandara, MD
UC Davis Health

Program Overview:

Recent advances and current landscape of molecular testing in NSCLC: What can we expect from new NGS and multiplex technologies?
Emerging NSCLC biomarkers of disease: How can we most efficiently use molecular testing to make driver mutations more actionable in clinical practice?
Panel discussion of real-world case studies of NSCLC testing in clinical practice

WATCH NOW

Every day matters. Why wait?

About the Test

With the rise of precision oncology, genomic profiling is playing an increasingly large role in clinical decision making and bringing clarity to targeted treatment approaches. Across all advanced cancer types, faster answers are needed.

Explore the benefits of the Oncotype MAP test

The Oncotype MAP Pan-Cancer Tissue Test delivers rapid, comprehensive tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer. The test identifies actionable genomic alterations within 3-5 business days to guide timely treatment decisions, usually before the next follow up visit.

Utilizing next generation sequencing (NGS) and a broad array of immunohistochemical (IHC) stains and panels, the Oncotype MAP Pan-Cancer Tissue Test identifies clinically-relevant genomic alterations from patient specimens as small as 3 mm² of tissue or 2-3 slides^‡. Fewer Quantity Not Sufficient (QNS) samples mean more of your patients get tested and treated.

REQUEST INFORMATION

Why Oncotype MAP Pan-Cancer Tissue Test?

FAST

Results in 3-5 business days

Quantity Not Sufficient (QNS) results typically reported within 48 hours

COMPREHENSIVE

>250 genes, 11 fusions

22 IHC stains

25+ disease specific panels

Copy number variants

Tumor mutation burden

Protein expression

ACTIONABLE

Test assesses:

100+ therapies

45+ combination therapies

650+ clinical trials

ACCURATE

FNA and FFPE samples as small as 3 mm² with ≥15% tumor content

>99% sensitivity for SNVs and Indels, detection down to ≥7.5% mutant allele frequency (MAF) with >99% specificity*

Actionable Indications for Therapies and Clinical Trials

Results are provided in an easy-to-interpret report with NCCN actionable indications for therapy, along with potential evidence-based therapies and clinical trials, to deliver treatment options for a breadth of solid tumor types.

EXPLORE SAMPLE REPORT

Comprehensive List of Genes and IHC Panels

The Oncotype MAP Pan-Cancer Tissue Test profiles a wide range of genetic structures including:

Single nucleotide variants (SNVs) and insertions/deletions in coding regions of the genes listed below
Untranslated regions (UTRs) and splice junctions when actionable, e.g. MET exon 14 skipping and EGFRvIII
Microsatellite instability (MSI)
Tumor mutational burden (SNVs, insertions, deletions) based on -1 megabase
Select fusions involving ALK, BRAF, FGFR1, FGFR2, FGFR3, MET, RET, ROS1, NTRK1, NTRK2, NTRK3 (ETV6)
Copy number variants

VIEW 257 NGS GENE PANEL

257 NGS Gene Panel
ABCB1 ABCC1 ABCC2 ABL1 ACVR1 ACVR1B ACVR2A ACVR2B ACVRL1 ADAMTS1 ADAMTS6 ADAMTS9 ADAMTS16 ADAMTS18 ADAMTSL1 AKT1 AKT2 AKT3 ALK AMER1 APC APLNR AR ARAF	AREG ARID1A ARID1B ARID2 ATM ATR ATRX AURKA AURKB AXIN1 AXL B2M BAP1 BARD1 BCOR BMP6 BMPR1A BMPR1B BNIP3 BRAF BRCA1 BRCA2 BRIP1 BTK	BUB1B CALR CBL CCND1 CCND2 CCND3 CCNE1 CD274 CDA CDC73 CDH1 CDK4 CKD6 CDK12 CDKN2A CHEK1 CHEK2 CHFR CHKA CIC CREBBP CSF1R CTLA4 CTNNB1	CYP19A1 CYP1A1 CYP2D6 CYP3A4 CYSLTR2 DCK DDR2 DICER1 DNMT3A EGFR EMSY EP300 EPCAM EPHA5 EPHA7 ERBB2 ERBB3 ERBB4 ERCC1 ERCC2 ERCC3 ERRFI1 ESR1 ESR2	EWSR1 EZH2 FAM175A FANCA FANCC FANCD2 FANCE FANCF FANCG FANCM FAT1 FBXW7 FCGR2A FGD4 FGF3 FGF4 FGFR1 FGFR2 FGFR3 FGFR4 FLT3 FLT4 FOXL2 FUBP1	GAS6 GATA3 GLI1 GNA11 GNAQ GNAS GSTP1 HAMP HDAC2 HGF HNF1A HRAS HSD3B1 IDH1 IDH2 IGF1R IKZF1 IL6R JAK1 JAK2 JAK3 KDM5C KDM6A KDR	KEAP1 KIT KRAS MAF MAP2K1 MAP2K2 MAP3K1 MAPK1 MAPK3 MAPKAPK5 MDM2 MDM4 MED12 MEN1 MET MGMT MLH1 MPL MRE11A MSH2 MSH6 MTHFR MTOR MUTYH	MYC MYCN MYOD1 NBN NF1 NF2 NFE2L2 NOTCH1 NOTCH2 NOTCH3 NPMI NRAS NTRK1 NTRK2 NTRK3 PALB2 PBRM1 PDCD1LG2 PDGFRA PDGFRB PIK3CA PIK3CB PIK3CD PIK3CG	PIK3R1 PIM1 PLCB4 PLCG1 PMS2 POLD1 POLE PP2R1A PTCH1 PTEN PTPN11 RAD50 RAD51C RAD51D RAF1 RB1 RBM10 RECQL RET RHEB RICTOR RIT1 RNF43 ROS1	RPTOR RRMI SDHB SDHC SETD2 SF3B1 SMAD1 SMAD2 SMAD4 SMAD5 SMAD9 SMARCA4 SMARCB1 SMO SOCS1 SPOP STAG2 STAT3 STAT5A STAT5B STK11 SUFU TERT-p TGFB1	TGFB2 TGFB3 TGFBR1 TGFBR2 TNFA1P3 TNK1 TOP2A TP53 TSC1 TSC2 TSHR TYMS VEGFA VHL WTI XRCC1 YES1

VIEW SINGLE IHC STAINS -and- TUMOR-SPECIFIC IHC PANELS

Single IHC Stains
ALK AR CAIX ER hENTI HER2 IDO	MET MGMT MLH1 MMR (4 IHC) MSH2 MSH6	PD1 PD-L1 (22C3) PD-L1 (SP142) PMS2 PR PTEN ROS1	TOP1 TP TRKpan TS TUBB3
Tumor-specific Panels
Anal Carcinoma: PD-L1 (22C3), PD-1, TS, TUBB3 Appendix: HER2, PD-L1 (22C3), TOP1, PTEN Bladder: PD-L1 (22C3), PD-L1 (SP142), hENTI, TUBB3 Bone Cancer: TOP1, MGMT, CAIX, HENTI Breast: AR, PD-L1(SP142), PD-L1 (22C3), TP CNS / Brain Cancers: MGMT, CAIX, TUBB3, TOP1 Cervical: PD-L1 (22C3), CAIX, hENTI, TOP1 Colorectal: HER2, PD-L1 (22C3), TOP1, PTEN, TS Gastric / Esophageal: HER2, PD-L1 (22C3), PTEN, TS GIST: PD-L1 (22C3), MET Head and Neck: PD-L1 (22C3), CAIX, TUBB3, PTEN Head and Neck Salivary Gland: HER2, AR, CAIX, PTEN Hepatobillary / Cholangiocarcinoma: hENTI, HER2, TP, PD-L1 (22C3) Hepatobillary / Gallbladder: hENTI, HER2, PD-L1 (22C3), TOP1 Hepatobillary / Hepatocellular: hENTI, PD-L1 (22C3), CAIX, MET Kidney: PD-L1 (22C3), MET, CAIX, hENTI Melanoma: PD-L1 (22C3), MGMT, PTEN, TUBB3 Mesothelioma: PD-L1 (22C3), TS, hENTI, TUBB3		MMR: MLH1, MSH2, MSH6, PMS2 Neuroendocrine: PD-L1 (22C3), MGMT, PTEN, TP NSCLC: PD-L1 (22C3), ALK, PD-L1 (SP142), PTEN, TS Ovarian: ER, HER2, TOP1, TUBB3 Pancreatic: hENTI, PTEN, TP, TOP1 Penile Cancer: PD-L1 (22C3), TP, CAIX, TUBB3 Prostate: AR, PTEN, TUBB3, PD-L1 (22C3) Sarcoma: CAIX, TUBB3, TOP1, MGMT SCLC: PD-L1 (22C3), TOP1, MGMT Small Bowel: TOPO1, CAIX, TUBB3, hENTI Testicular Cancer: PD-L1 (22C3), TUBB3, hENTI Thyroid: PD-L1 (22C3), ALK, TUBB3, CAIX Thymoma / Thymic Carcinoma: PD-L1 (22C3), TUBB3, hENTI, TS Uterine: PD-L1 (22C3), HER2, MGMT, TUBB3 Uveal Melanoma: PD-L1 (22C3), MGMT, TUBB3 Vulvar Cancer: PD-L1 (22C3), CAIX, TUBB3, hENTI Other Solid Tumors: PD-L1 (22C3), HER2, TOP1, PTEN, TS

Oncotype MAP Pan-Cancer Tissue test helps guide therapy selection today and captures emerging clinical trial markers that may find their way into guidelines tomorrow.

ORDER NOW

Shipping Instructions

Step 1

Place the Oncotype MAP Requisition Form, a copy of the pathology report, and relevant patient demographics and insurance materials in the Oncotype MAP Pan-Cancer Tissue Kit.

Step 2

Place the Oncotype MAP Specimen Kit into the FedEx® Clinical Pak. DO NOT include any patient identifiers on the Specimen Kit.

Step 3

The airbill is pre-printed with Exact Sciences shipping information for your convenience.
BE SURE TO MARK SERVICE AS “PRIORITY OVERNIGHT”.

Step 4

Seal the Clinical Pak by removing the plastic adhesive protector from the white strip and secure.

Step 5

Place the package in the designated FedEx pickup location at your site.

Questions?

Contact Customer Service at  866-ONCOTYPE (662-6897).

Additional Resources

 Download Test Overview

 Download Specimen Submission Guidelines

 Download Sample Report

 Download Billing Overview

Commitment to Patient Genomic Access

Exact Sciences is committed to supporting patient access to Oncotype MAP Pan-Cancer tissue test to support patients in making informed decisions about their treatment. Medicare covers Oncotype MAP Pan-Cancer tissue test for qualifying members. Commercial coverage varies by insurance plan and patient benefit level. Exact Sciences strongly encourages patients to contact their insurance carrier to better understand their benefits plan. Regardless of network status, all commercial health plan coverage is pursuant to the applicable health plan’s medical policy and specific patient benefit levels. Exact Sciences offers Financial Assistance if a patient is uninsured or concerned about their ability to pay for the out-of-pocket cost of testing.

LEARN ABOUT BILLING

Oncotype MAP Product Updates

REFERENCES

*Data on File, In-house assay optimization protected by trade-secret/patent regulations
† Turnaround time is based on qualified sample receipt.
‡ Morris S, Subramanian J, Gel E, Runger G, Thompson E, Mallery D, et al. Performance of next-generation sequencing on small tumor specimens and/or low tumor content samples using a commercially available platform. PLoS ONE. (2018); 13(4): e0196556. https://doi.org/10.1371/journal.pone.0196556

Oncotype MAP Pan-Cancer Tissue Test

Providing answers physicians need at the speed patients deserve

Comprehensive genomic profiling to aid therapy selection in advanced cancer within 3-5 business days* †